Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals (Nasdaq: MRNS) announced upcoming presentations at the Neurocritical Care Society 22nd Annual Meeting, October 14-17 in San Diego. The presentations will feature:
- Additional data from the Phase 3 RAISE trial on intravenous ganaxolone for refractory status epilepticus
- A retrospective claims-based analysis on status epilepticus management
Key presentations include:
- A podium presentation on October 17 by Dr. Brandon Foreman, discussing efficacy and safety results from the RAISE trial
- A poster presentation on October 16 by Dr. Henrikas Vaitkevicius, focusing on challenges in status epilepticus management, particularly high rates of interhospital transfers
Marinus Pharmaceuticals (Nasdaq: MRNS) ha annunciato presentazioni imminenti al 22° Congresso Annuale della Neurocritical Care Society, dal 14 al 17 ottobre a San Diego. Le presentazioni includeranno:
- Ulteriori dati dal trial di Fase 3 RAISE sull'uso del ganaxolone endovenoso per l'epilessia da stato refrattario
- Un analisi retrospettiva basata su richieste sulla gestione dell'epilessia da stato
Le presentazioni chiave includeranno:
- Una presentazione al podio il 17 ottobre da parte del Dr. Brandon Foreman, che discuterà i risultati di efficacia e sicurezza del trial RAISE
- Una presentazione poster il 16 ottobre da parte del Dr. Henrikas Vaitkevicius, che si concentrerà sulle sfide nella gestione dell'epilessia da stato, in particolare sui tassi elevati di trasferimenti interospedalieri
Marinus Pharmaceuticals (Nasdaq: MRNS) anunció próximas presentaciones en la 22ª Reunión Anual de la Neurocritical Care Society, del 14 al 17 de octubre en San Diego. Las presentaciones incluirán:
- Datos adicionales del ensayo de Fase 3 RAISE sobre ganaxolona intravenosa para el estado epiléptico refractario
- Un análisis retrospectivo basado en reclamaciones sobre la gestión del estado epiléptico
Las presentaciones clave incluirán:
- Una presentación en el podio el 17 de octubre por el Dr. Brandon Foreman, donde discutirá los resultados de eficacia y seguridad del ensayo RAISE
- Una presentación de póster el 16 de octubre por el Dr. Henrikas Vaitkevicius, centrada en los desafíos en la gestión del estado epiléptico, especialmente las altas tasas de transferencias interhospitalarias
마리누스 제약(MSN: MRNS)은 10월 14일부터 17일까지 샌디에고에서 열리는 제22회 신경중환자 치료학회 연례 회의에서 향후 발표를 발표했습니다. 발표 내용은 다음과 같습니다:
- 내성 상태 간질에 대한 정맥 주사 가나졸론의 3상 RAISE 시험의 추가 데이터
- 상태 간질 관리에 대한 청구 기반의 회고적 분석
주요 발표에는:
- 10월 17일 브랜든 포어맨 박사의 포디엄 발표가 포함되어 있으며, RAISE 시험의 효과 및 안전성 결과에 대해 논의합니다.
- 10월 16일 헨리카스 바이트케비시우스 박사의 포스터 발표가 포함되어 있으며, 상태 간질 관리의 문제, 특히 병원 간 이송의 높은 비율에 집중합니다.
Marinus Pharmaceuticals (Nasdaq: MRNS) a annoncé des présentations à venir lors de la 22e Réunion Annuelle de la Neurocritical Care Society, du 14 au 17 octobre à San Diego. Les présentations comprendront :
- Données supplémentaires de l'essai de Phase 3 RAISE sur le ganaxolone intraveineux pour l'état de mal épileptique réfractaire
- Une analyse rétrospective basée sur des revendications sur la gestion de l'état de mal épileptique
Les présentations clés incluront :
- Une présentation au podium le 17 octobre par le Dr Brandon Foreman, discutant des résultats d'efficacité et de sécurité de l'essai RAISE
- Une présentation par affiche le 16 octobre par le Dr Henrikas Vaitkevicius, axée sur les défis de la gestion de l'état de mal épileptique, notamment les taux élevés de transferts interhôpitaux
Marinus Pharmaceuticals (Nasdaq: MRNS) kündigte kommende Präsentationen auf dem 22. Jahrestreffen der Neurocritical Care Society vom 14. bis 17. Oktober in San Diego an. Die Präsentationen werden Folgendes umfassen:
- Zusätzliche Daten aus der Phase-3-RAISE-Studie über intravenöses Ganaxolon zur Behandlung refraktärer Status-Epileptikus
- Eine retrospektive Anspruchsanalyse zur Behandlung des Status-Epileptikus
Wichtige Präsentationen umfassen:
- Eine Podiumspräsentation am 17. Oktober von Dr. Brandon Foreman, der die Wirksamkeits- und Sicherheitsdaten der RAISE-Studie diskutiert
- Eine Posterpräsentation am 16. Oktober von Dr. Henrikas Vaitkevicius, die sich mit den Herausforderungen im Management des Status-Epileptikus, insbesondere der hohen Transferquote zwischen Krankenhäusern, beschäftigt
- Phase 3 RAISE trial data on intravenous ganaxolone for refractory status epilepticus to be presented
- Company's research selected for podium presentation at major neurocritical care conference
- Additional retrospective claims-based analysis on status epilepticus management to be presented
- None.
Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE
Presentation details are as follows:
Podium Presentation Details:
Thursday, October 17, 2024, 9:35-9:55 a.m. PT
- Title: Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial
-
Presenting Author: Brandon Foreman, M.D., M.S., FACNS, FNCS, Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery at the University of
Cincinnati and Associate Director for Neurocritical Care Research - Session: Late-Breaking Science Oral Platform
Poster Presentation Details:
Wednesday, October 16, 2024, 2:45-3:45 p.m. PT
- Title: High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care
- Presenting Author: Henrikas Vaitkevicius, M.D., VP, Clinical Development, Marinus Pharmaceuticals
- Session: Poster Session Day 2
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009774652/en/
Investors
Sonya Weigle
Chief People and Investor Relations Officer
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
What will Marinus Pharmaceuticals (MRNS) present at the Neurocritical Care Society 2024 Annual Meeting?
When and where is the Neurocritical Care Society 2024 Annual Meeting where Marinus Pharmaceuticals (MRNS) will present?
Who will present the podium presentation for Marinus Pharmaceuticals (MRNS) at the NCS 2024 Annual Meeting?
What is the topic of the poster presentation by Marinus Pharmaceuticals (MRNS) at the NCS 2024 Annual Meeting?
